Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8

Stefan Bauer, Nicole Adrian, Uta Siebenborn, Natalie Fadle, Margarita Plesko, Eliane Fischer, Thomas Wüest, Frank Stenner, Joachim C. Mertens, Alexander Knuth, Gerd Ritter, Lloyd J. Old and Christoph Renner
Stefan Bauer
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Adrian
2Med. Department I, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uta Siebenborn
2Med. Department I, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Fadle
2Med. Department I, Saarland University, Homburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Margarita Plesko
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eliane Fischer
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Wüest
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Stenner
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim C. Mertens
3Medical Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Knuth
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerd Ritter
4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd J. Old
4Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan Kettering Cancer Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoph Renner
1Oncology Department, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2009
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Preparation and characterization of scFv constructs. (A) Scheme of the constructs for anti-FAP scFv, anti-FAP scFv-IL-872 and anti-FAP scFv-IL-83-72 as they were inserted into the mammalian expression vector pEAK8. The anti-FAP scFv antibody vector consisted of the promoter-leader cassette coding for an 18-aa secretory leader sequence, the variable heavy chain region followed by a 10-aa linker with the light chain variable region and a DNA sequence encoding a c-myc and His6 tag at the C-terminus for detection and affinity purification. IL-8 variants are N-terminally linked to anti-FAP scFv by (Ser4Gly)3. (B) Anti-FAP scFv-IL-8 (lanes 1 to 3) and anti-FAP scFv-IL-83-72 (lanes 4 to 6) were purified by immobilized metal chelate chromatography. Culture supernatant (lanes 1 and 4), flow through (lanes 2 and 5) and purified constructs (lanes 3 and 6) were analyzed by SDS-PAGE under reducing conditions. As expected, bands corresponding to scFv IL-8 variants were detected at 39 kDa (lane 3 for anti-FAP scFv-IL-872 and lane 6 for anti-FAP scFv-IL-83-72). (C) Western blot analysis of anti-FAP scFv (lanes 1 and 4), anti-FAP scFv-IL-872 (lanes 2 and 5) and anti-FAP scFv IL-83-72 (lanes 3 and 6) stained with anti-c-myc (lanes 1 to 3) and anti-hu IL-8 antibody (lanes 4 to 6).

  • Figure 2
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2

    Binding properties of scFv constructs. (A) Flow cytometry analysis of constructs [anti-FAP scFv (thick line), anti-FAP scFv-IL-83-72 (dotted line) and anti-FAP scFv-IL-872 (thin line)] was performed on FAP-transfected HT1080 cells. An anti-CD30 scFv-IL-8 fusion protein served as negative control. Binding was detected by monoclonal anti-c-myc antibody. (B) Recognition of targeted antigen by scFv constructs was performed by incubation with rabbit anti-human IL-8 and visualized by PE-conjugated goat anti-rabbit serum. Uncoupled parental anti-CD30 scFv-IL-8 was used as negative control. (C) Binding of scFv variants to immobilized anti-FAP-anti-ID was visualized by rabbit anti-IL-8 serum using ELISA. Uncoupled anti-FAP scFv and anti-CD30 scFv-IL-8 were used as controls. Measurements were carried out in triplicate samples; standard deviations are indicated by the bars.

  • Figure 3
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3

    Chemotactic potential of anti-FAP scFv-IL-8 variants in vitro. We used a fluorescence-based end-point assay to measure PMN migration in vitro. Chemo-attractants (rhu IL-8, anti-FAP scFv, anti-FAP scFv-IL-83-72 and anti-FAP scFv-IL-872) and controls were diluted in PBS-HSA 0.1%. PBS-HSA 0.1% alone was used to determine random migration. In order to define the total fluorescence of PMNs, calcein-AM labeled PMNs were placed directly at defined concentrations (80000, 8000, 800 and 80 cells) in three separate wells. 80000 PMNs were placed directly onto the top of the filter and the chamber was incubated for 60 minutes. The total number of PMNs that had migrated to the lower chamber was measured with a fluorescence plate reader. Measurements were carried out in triplicate samples. The standard deviation of three assays is shown.

  • Figure 4
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4

    Kinetics of FAP expression of transfected HT1080-FAP+ fibrosarcoma cells in vitro and in vivo. (A) FAP transfected HT1080 cells were cultured without G418 selective pressure and the levels of antigen density were measured after 3 weeks by FACScan analysis. (B to E) Immunohistochemical staining of HT1080-FAP+ xenograft fibrosarcoma cells showing positive staining over a period of four weeks. 5 x 106 cells were injected s.c. in BALB/c nu/nu mice. Solid tumors were harvested after 14 (B, C) and 28 days (D, E), respectively. Tissue sections were stained with anti-FAP IgG (B, D) or with anti-G250 IgG (C, E) as a control. Bars correspond to 10 µm.

  • Figure 5
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5

    Targeted antigen-dependent recruitment of PMNs to FAP-expressing tumors. Fibrosarcomas were established in BALB/c nu/nu mice by s.c. injection of 5 x 106 FAP-transfected and mock-transfected HT1080 cells, respectively. FAP-positive (left column) and -negative (right column) tumors were simultaneously established at the opposite flanks of the animals. Tumors were harvested 24 hours after i.v. injection of a total dose of 300 µg scFv-IL872 (equivalent to 100 µg rhu IL-8). (A, B) FAP expression of xenografts was confirmed by anti-FAP mAb staining. PECAM-1-positive tumor vessels were visualized to define comparable areas of FAP-positive (C) or -negative (D) fibrosarcomas to exclude unspecific PMN accumulation. Staining with anti-CD11b mAb demonstrated the targeted antigen-specific delivery of scFv-IL872 by chemokine-triggered enrichment of PMNs (E, F). Bars correspond to 100 µm.

  • Figure 6
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6

    Effects of sequential immunotherapy on the growth pattern of tumor xenografts. (A) FAP positive tumors were established in BALB/c nu/nu mice by s.c. injection 5 x 106 HT1080 FAP+ cells and mice randomly assigned to different treatment groups at day nine. For sequential immunotherapy, effector constructs were injected i.v. and followed eight hours later by i.v. injection of the second effector construct as indicated (100 µl per injection). This treatment regimen was repeated every three days as highlighted by the arrows (five times in total). Starting on day 21, the growth delay was statistically significant for the anti-FAP TNF & anti-FAP scFv-IL-872 group (*, P < 0.001) when compared to all other treatment groups. Comparison of tumor sizes between the anti-FAP TNF and the anti-FAP TNF & rhu IL-8 group and the remaining groups was also significant at this time point (**, P < 0.001), but tumor sizes did not differ significantly between the anti-FAP TNF and the anti-FAP TNF & rhu IL-8 group. Single agent treatment with anti-FAP scFv-IL-872 also resulted in significant (***, P < 0.001) anti-tumor effects when compared to the rhu IL-8-containing regimens that did not differ from the PBS group (data not shown). Treatment results stayed significant over the observation period. Animals were taken off study when tumor volume exceeded 1 cm3. (B) Delay of tumor growth of mice receiving anti-FAP TNF & anti-FAP scFv IL-8 was linked to antigen expression. Simultaneous growth of two phenotypically different xenografts [FAP-positive (closed symbols) and FAP-negative (open symbols)] was established in nude mice and animals assigned to their respective treatment group when tumor diameter reached 5 mm. Again, animals were treated with anti-FAP TNF & anti-FAP scFv-IL-872 following the sequential application schedule indicated by the arrows. Mice had to be taken off study when the volume of FAP-negative xenografts exceeded 1 cm3. At this time point, differences in tumor size between FAP-positive and -negative xenografts were statistically significant (*, P < 0.001).

PreviousNext
Back to top
Cancer Immunity Archive: 9 (1)
January 2009
Volume 9, Issue 1
  • Table of Contents

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8
Stefan Bauer, Nicole Adrian, Uta Siebenborn, Natalie Fadle, Margarita Plesko, Eliane Fischer, Thomas Wüest, Frank Stenner, Joachim C. Mertens, Alexander Knuth, Gerd Ritter, Lloyd J. Old and Christoph Renner
Cancer Immun January 1 2009 (9) (1) 2;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8
Stefan Bauer, Nicole Adrian, Uta Siebenborn, Natalie Fadle, Margarita Plesko, Eliane Fischer, Thomas Wüest, Frank Stenner, Joachim C. Mertens, Alexander Knuth, Gerd Ritter, Lloyd J. Old and Christoph Renner
Cancer Immun January 1 2009 (9) (1) 2;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and methods
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • NY-ESO-1–specific immunological pressure and escape in a patient with metastatic melanoma
  • Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis
  • Human ovarian tumor ascites fluids rapidly and reversibly inhibit T cell receptor-induced NF-κB and NFAT signaling in tumor-associated T cells
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement